Currax Pharmaceuticals names new SVP, CMO
11 January 2022 -

Currax Pharmaceuticals LLC, a specialty biopharmaceutical company, announced on Monday that it has named Dr Michael Kyle as its new senior vice president, chief medical officer.

Dr Kyle is to report to George Hampton, Currax Pharmaceuticals' president and chief executive officer. In the new role, Dr Kyle will be responsible for the company's regulatory, medical affairs, clinical development/operations, and the pharmacovigilance organisation for the company. He will also head the company's exploration of smoking cessation opportunities through the CX-101 program.

Dr Kyle has served as the head of Development at Jiangsu HengRui Pharmaceuticals, and prior to that he held various roles in both clinical development and medical affairs at Pfizer, including: US medical director of Established Products, Medical Affairs; chief medical officer, Pfizer Consumer Health; and vice president, head of Global Clinical Services and Operations of Upjohn, a Pfizer Division.